Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
NEW YORK, Sept. 25, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Pennsylvania on behalf of investors who purchased Teva Pharmaceutical Industries Ltd. ("Teva") (NYSE:TEVA) American Depositary Shares between November 15, 2016 and August 2, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sbm/teva-pharmaceutical-industries-ltd?wire=3. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose adverse information concerning the Company’s business and outlook. In particular, it is alleged that Teva failed to disclose and/or omitted the true negative impact of the acquisition and integration of Actavis Generics on the Company’s financial results and business prospects.
If you suffered a loss in Teva you have until October 23, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sbm/teva-pharmaceutical-industries-ltd?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
